Related Experiment Videos
ASA-dipyridamole prophylaxis in elective total hip replacement
Orthopedics
|January 1, 1978
Summary
This study found that combining dipyridamole and acetylsalicylic acid (ASA) did not effectively prevent venous thromboembolism after hip replacement surgery. The drug combination showed no benefit over placebo in reducing postoperative thrombosis risks.
Area of Science:
- Orthopedic Surgery
- Pharmacology
- Vascular Medicine
Background:
- Postoperative venous thromboembolism (VTE) is a significant risk following elective total hip replacement (THR).
- Prophylaxis strategies aim to mitigate VTE, but optimal regimens require ongoing evaluation.
Purpose of the Study:
- To assess the efficacy of combined dipyridamole and acetylsalicylic acid (ASA) for VTE prophylaxis in elective THR.
- To compare the incidence of thrombosis in patients receiving the drug combination versus placebo.
Main Methods:
- Prospective, double-blind, randomized clinical trial.
- Patients received either dipyridamole (225 mg/day) plus ASA (1 gm/day) or placebo.
- 125I-labeled fibrinogen scanning and venography were used to detect thrombosis postoperatively.
Main Results:
- Overall VTE incidence was 30% (40/132 patients).
- Thrombosis occurred in 25% (17/68) of the control group and 36% (23/64) of the treated group.
- No clinically significant pulmonary emboli were observed in either group.
Conclusions:
- The combination of dipyridamole and ASA, as administered, is not effective for VTE prophylaxis in elective THR.
- Further research may be needed to explore alternative or optimized prophylactic regimens.